Skip to main content
Premium Trial:

Request an Annual Quote

Agilent s LSCA Unit Grows 3 Percent in Fiscal Q2 as Total Receipts Slide 8 Percent

NEW YORK, May 17 (GenomeWeb News) - Agilent Technologies yesterday reported an 8-percent drop in revenues and decreased earnings for its second fiscal quarter, though contributions from the life sciences and chemical analys segment grew 3 percent.

 

Revenue for the quarter ended April 30 fell to $1.7 billion from $1.8 billion during the same period last year. Receipts from the company's life sciences and chemical analysis segment increased to $344 million from $333 during the same quarter.

 

Research and development costs increased slightly, to $248 million from $237 million during the second quarter of 2004.

 

Net earnings for the quarter fell to $95 million, or $.19 per share, from $104 million, or $.21 per share, during the year-ago period.

 

As of April 30, Agilent had $2.7 billion in cash and cash equivalents.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.